03:43 PM EDT, 06/26/2024 (MT Newswires) -- (Updates with the latest stock movement in the headline and first paragraph with additional information)

Moderna's ( MRNA ) shares were down 10.3% in recent Wednesday trading after the Centers for Disease Control and Prevention reported a significant drop in the efficacy of the company's respiratory syncytial virus vaccine in the second year, which is now lower than that of rival vaccines.

Moderna ( MRNA ) presented the data at a meeting of the CDC's Advisory Committee on Immunization Practices.

Moderna's ( MRNA ) RSV shot "mRESVIA" dropped from 55% efficacy over the first 12 months to 36% in year two in patients with at least three "lower respiratory" symptoms of RSV. Meanwhile, Pfizer's ( PFE ) shot declined from 86% efficacy in year one to 74% in year two, while GSK's (GSK) fell from 79% to 59%, according to a CDC presentation.

Moderna ( MRNA ), Pfizer ( PFE ) and GSK did not immediately respond to MT Newswires' requests for comment.

Price: 123.51, Change: -14.09, Percent Change: -10.24